Brand Intelligence Graphcompany
Company Overview
About Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Business Model & Competitive Advantage
BMS's diversified biopharmaceutical model addresses the pharmaceutical industry's central challenge of sustaining revenue as patent-protected blockbusters lose exclusivity: Revlimid's patent cliff (generic erosion accelerating through 2026) is being offset by the Growth Portfolio — which includes newer products with longer exclusivity runways and novel mechanisms of action that extend patent protection. The company's integrated discovery-to-commercialization model enables BMS to identify novel biological targets (particularly in immuno-oncology and targeted therapy), advance candidates through clinical development, obtain FDA approval, and deploy its global commercial infrastructure to generate peak sales from premium-priced specialty medicines. The Cobenfy acquisition represents a rare non-dopamine mechanism for schizophrenia treatment — the first new schizophrenia mechanism in decades — addressing a $10B+ market opportunity with differentiated clinical profile.
Competitive Landscape 2025–2026
In 2025, BMS competes in global oncology, immunology, and neuroscience pharmaceuticals against Pfizer (NYSE: PFE, $58.5B 2024 revenue), AstraZeneca (NASDAQ: AZN, $54.1B 2024 revenue), and Merck (NYSE: MRK, $63.6B 2024 revenue) for oncology market share, new drug approvals, and pipeline partnership opportunities. The Karuna ($14B), Mirati ($4.8B), and RayzeBio ($4.1B) acquisitions collectively add ~$23B in pipeline value and expand BMS into three high-growth therapeutic areas: CNS/neuroscience (Cobenfy), KRAS-targeted oncology, and radiopharmaceuticals. The 2025 strategy under CEO Boerner prioritizes integrating the acquired pipelines, building commercial infrastructure for Cobenfy's schizophrenia launch, advancing the radiopharmaceutical platform from early clinical to pivotal trials, and managing the Revlimid generics headwind through continued Growth Portfolio expansion.
The Bristol Myers Squibb Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Bristol Myers Squibb's journey
Leadership Team
Meet the leaders behind Bristol Myers Squibb
Dr. Christopher Boerner
Dr. Boerner, 54, became CEO in November 2023 and Board Chair in April 2024. He brings extensive pharmaceutical experience and strategic vision to lead BMS through its portfolio transition and continued growth through innovation and acquisitions.
David V. Elkins
Mr. Elkins has served as CFO since 2019, overseeing the company's financial strategy through major acquisitions including Celgene, Mirati, RayzeBio, and Karuna. He regularly represents BMS at major investor conferences.
Sandra Leung
Ms. Leung serves as the company's top legal executive, providing strategic counsel on regulatory matters, corporate governance, and major transactions that have shaped BMS's growth trajectory.
Adam Lenkowsky
A 27-year BMS veteran who started as a sales representative, Mr. Lenkowsky oversees the commercialization of BMS's entire portfolio. Named an Elite 2024 Transformational Leader by PM360 for his leadership during the Mirati, RayzeBio, and Karuna acquisitions.
Amanda Poole
Ms. Poole joined the executive team in 2024, leading human resources strategy, talent development, and the company's award-winning workplace culture initiatives focused on inclusion and employee wellbeing.
Dr. Cristian Massacesi
Dr. Massacesi joined BMS in August 2025, bringing medical expertise to oversee clinical development programs across oncology, immunology, cardiovascular, and hematology therapeutic areas.
Key Differentiators
Market Leader
Bristol Myers Squibb is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Bristol Myers Squibb with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Bristol Myers Squibb? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Bristol Myers Squibb Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Bristol Myers Squibb vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →